1 – 26 of 26
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
(
- Contribution to journal › Article
- 2023
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
- 2022
-
Mark
Advances in immune therapies in hematological malignancies
(
- Contribution to journal › Scientific review
-
Mark
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients
(
- Contribution to journal › Article
-
Mark
Noninvasive detection of any-stage cancer using free glycosaminoglycans
(
- Contribution to journal › Article
- 2021
-
Mark
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
(
- Contribution to journal › Article
- 2018
-
Mark
Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
- 2017
-
Mark
Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
(
- Contribution to journal › Article
- 2016
-
Mark
Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma : a Swedish Lymphoma Registry study
(
- Contribution to journal › Article
- 2015
-
Mark
The impact of age on survival of diffuse large B-cell lymphoma - a population-based study
(
- Contribution to journal › Article
-
Mark
Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study
(
- Contribution to journal › Article
-
Mark
Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.
(
- Contribution to journal › Article
- 2011
-
Mark
Long term risk of infections in Hodgkin lymphoma long-term survivors.
(
- Contribution to journal › Letter
-
Mark
TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia
(
- Contribution to journal › Article
- 2009
-
Mark
Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors-Retrospective cohort analyses and a concept for prospective intervention
(
- Contribution to journal › Article
-
Mark
BCL2 expression in de novo Diffuse Large B-cell Lymphoma partly reflects normal differences in age distribution
(
- Contribution to journal › Letter
-
Mark
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
(
- Contribution to journal › Article
- 2008
-
Mark
Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
- 2007
-
Mark
Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma
(
- Contribution to journal › Letter
-
Mark
Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN
(
- Contribution to journal › Article
- 2003
-
Mark
Early and intermediate stage Hodgkin's lymphoma - report from the Swedish National Care Programme.
(
- Contribution to journal › Article